INDIANAPOLIS, June 5, 2017 /PRNewswire/ -- Bruker is
show-casing several new and innovative, high-performance mass
spectrometry solutions for metabolomics, proteoform profiling and
toxicology at ASMS 2017 (www.asms.org). Bruker is also celebrating
25 years of MALDI innovation with an emphasis on robust,
high-throughput MALDI analytical, clinical and imaging
solutions.
Frank H. Laukien, Ph.D., Bruker's
President and CEO, commented: "At ASMS 2017, we are introducing
novel and performance-leading mass spectrometry solutions for
life-science and translational research markets, as well as for
pharmaceutical and applied markets. Our advanced MALDI
Imaging solutions now integrate the industry-leading
SCiLS mass-spec imaging software with the
rapifleX high-throughput MALDI-TOF/TOF system, or the
novel MALDI-Magnetic Resonance Mass Spectrometry (MRMS) extreme
resolution system for drug and metabolite tissue imaging. We are
also show-casing our unique timsTOF research system,
novel Metabolomics research and Phenomics
translational research solutions, a breakthrough Proteoform
Profiling solution, and a new robust, routine forensic
Toxicology platform. In 2017, we are also celebrating 25
years of MALDI innovation, an ionization technique that has enabled
pioneering breakthroughs in proteomics, microbiology, imaging and
high-throughput screening for drug discovery."
A. Pharmaceutical and Translational Mass
Spectrometry Imaging
The new SCiLS Cloud and SCiLS
Lab software solutions, now with MultiVendor Support (MVS),
bring innovative software features to mass spectrometry imaging
(MSI) applications. MALDI Imaging has rapidly developed as a
label-free technique for spatially resolved molecular analysis of
proteins, glycans, lipids, as well as drugs and their metabolites.
MALDI Imaging is finding rapidly increasing use in pharmaceutical
drug development, in tissue-resolved biomarker research (e.g.
glycans on cell surfaces as cancer markers), as well as in
translational pathology research to complement immunohistochemistry
(IHC).
![SCiLS Lab SCiLS Lab](https://mma.prnewswire.com/media/519379/Bruker_Corporation_SCiLS_Lab_ASMS2017.jpg)
The new SCiLS Cloud software offers web-based
tools to facilitate distributed workflows, where data and analysis
results can be shared, viewed and manipulated with a web browser
through secure access. SCiLS Lab provides advanced and
user-friendly solutions for data handling, visualization and
computational analysis for Bruker MALDI imaging data sets, and now
also offers support for data acquired from non-Bruker mass
spectrometers.
Dr. Ron Heeren, Professor
at the University of Maastricht and
scientific director of the Maastricht MultiModal Molecular Imaging
Institute (M4I), commented: "We use mass spectrometry imaging
techniques at M4I with the aim to develop and apply mass
spectrometry as a diagnostic and prognostic tool for personalized
medicine in oncology, neurology and cardiovascular medicine.
Powerful and user-friendly software is essential for mining the
huge amount of data which is generated in MSI experiments. At M4I
we already used SCiLS Lab for our Bruker MALDI Imaging system for
years. We are now looking forward to expand SCiLS deployment to the
entire lab and to our portfolio of mass-spec equipment."
More…
B. Metabolomics and Proteoform Profiling
for Life-Science and Translational Research
Bruker introduces its third-generation metabolomics research and
validation solution,
MetaboScape® 3.0,
which has powerful new features essential for discovery
metabolomics, including support for direct-injection (DI) or MALDI
Magnetic Resonance Mass Spectrometry (MRMS) for high-throughput
phenomics translational research and validation. Innovations
include a novel algorithm called
Time-aligned-Region-complete-eXtraction
('T-ReX'), which automatically extracts all relevant
information in sample cohorts in a "region complete" manner.
Included in MetaboScape 3.0 are workflows that
support evaluating high-throughput, chromatography-free DI-MRMS or
MALDI-MRMS data, enabling two powerful extreme mass resolution
techniques that enable higher sample throughput for profiling
complex metabolic extracts. The speed and high throughput of these
MRMS methods yields advantages for validating larger sample
cohorts, and enabling larger-scale longitudinal studies.
![MetaboScape 3.0 MetaboScape 3.0](https://mma.prnewswire.com/media/519380/Bruker_Corporation_MetaboScape3_ASMS2017.jpg)
Professor Philippe
Schmitt-Kopplin at the Helmholtz Zentrum for Analytical
BioGeoChemistry in Munich,
Germany, elaborated: "We set up new discovery approaches
to describe the compositional space of any complex system in
biology and geochemistry. The eXtreme Resolution of Magnetic
Resonance Mass Spectrometry (MRMS) enables us to address
next-generation "metabotyping", i.e. simultaneous rapid description
of hundreds of known and thousands of new metabolites relevant for
dynamic biological/chemical processes. MRMS in combination with
MetaboScape will also enable other researchers to shed light onto
this new and exciting research field of exploring the yet 'dark
metabolome'." More…
Bruker's novel Proteoform Profiling™ 1.0 solution
enables a powerful new life-science research and translational
research workflow, i.e. the systematic, large-scale, label-free
study of all expressed proteoforms, including protein mutations,
splice variants, post-translational modifications, as well as
protein processing or degradation products. Detailed proteoform
characterization is of tremendous importance in cell biology and in
clinical proteomics research, where traditional bottom-up
proteomics analysis of digested proteins scrambles key biological
information. While the human genome only has about 25-30,000 coding
sequences, or 'genes', for transcription and translation into
protein families, the human body may have up to 1 billion different
proteoforms expressed.
Bruker's new nanoElute® nano-flow UHPLC system,
together with the new Proteoform Profiling™ 1.0
solution, aims to bring enhanced ease-of-use to nano-spray mass
spectrometry, which is essential for label-free discovery workflows
on intact protein mixtures.
Professor Leonard Foster at
the Department of Biochemistry & Molecular Biology of the
University of British Columbia in
Vancouver, Canada, stated:
"LC-MS experts and biologists alike require trouble-free
operation and ease-of-use, along with top performance. Our
experience has shown that the nanoElute system readily meets
those high demands."
Both innovations take advantage of the superior performance of
Bruker's impact II and ETD-enabled maXis
II UHR-QTOFs, which deliver accurate and reproducible
proteoform profiles from complex intact, undigested protein
mixtures. Unlike common Top-Down approaches, these UHR-QTOFs
deliver information from proteoform mixtures with a reduced level
of pre-fractionation, enabling the analysis of large sample sets
from clinically relevant cohorts, or for longitudinal studies. The
Proteoform Profiling 1.0 workflow automates the use
of Bruker's proprietary Dissect™ and SNAP™
algorithms, together with advanced molecular filtering functions,
to generate a non-redundant list of monoisotopic masses,
intensities and retention time from the isotopically resolved
proteins. More…
C. Applied Toxicology and
Forensics
Bruker announces the release of TargetScreener
3.0HR (high-resolution), which includes TASQ™
1.4 (Target Analysis for Screening and Quantitation)
software to provide a unified software platform for automated
screening and quantitative applications
in forensic, food and environmental safety markets. Bruker also
launches the ToxTyper 2.0E solution for routine,
high-throughput forensic toxicology with further improved
capabilities and database updates, to enhance customer
productivity.
![TargetScreener 3.0HR TargetScreener 3.0HR](https://mma.prnewswire.com/media/519383/Bruker_Corporation_TargetScreener_ASMS2017.jpg)
George W. Hime, M.S.,
Assistant Laboratory Director at the Miami-Dade Medical Examiner's Toxicology
Laboratory in Miami, Florida,
said: "The Toxtyper has been our go-to instrument for
post-mortem casework containing novel substances, substances that
are otherwise undetectable via GC-MS, and unknown substances we
have not yet seen in the lab. This instrument has been a blessing
to our laboratory over the last few years of dealing with the flood
of new illegal drugs in Miami.
From synthetic cathinones to synthetic fentanyls, we have detected
and identified them all reliably and with high confidence."
Further improvements in the new ToxTyper 2.0E
solution for automated toxicology integrates Bruker's newly
launched line of Elute UHPLC liquid chromatography
systems. With an expanded curated toxicology screening database and
new automated software for LIMS sample table I/O, automated
parallel processing with TASQ, and automated
reporting of results, these solutions enable increased throughput
while minimizing false positives and increasing confidence for
routine 'push-button' forensic toxicology. More…
Please join us at Bruker's ASMS Booth #518 throughout the
conference, and at our press conference on Monday, June 5, 2017, at 9:30 am EDT at the JW Marriott Indianapolis, 3rd
floor, JW Grand Ballroom. For more information:
www.bruker.com/events/2017/mass-spectrometry/asms-2017
About Bruker Corporation (NASDAQ: BRKR)
For more than
55 years, Bruker has enabled scientists to make breakthrough
discoveries and develop new applications that improve the quality
of human life. Bruker's high-performance scientific instruments and
high-value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels.
In close cooperation with our customers, Bruker is enabling
innovation, productivity and customer success in life science
molecular research, in applied and pharma applications, and in
microscopy, nano-analysis and industrial applications. In recent
years, Bruker has also become a provider of high-performance
systems for cell biology, preclinical imaging, clinical phenomics
and proteomics research, clinical microbiology, and for molecular
pathology research. For more information, please visit:
www.bruker.com
Media
Contact:
|
Investor
Contact:
|
Petra
Scheffer
|
Miroslava
Minkova
|
Daltonics Division
Marketing & Communications
|
Bruker Head of
Investor Relations
|
T: +49 (421)
2205-2843
|
T: +1 (978) 663-3660,
ext. 1479
|
E:
mailto:petra.scheffer@bruker.com
|
E:
miroslava.minkova@bruker.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bruker-introduces-novel-mass-spectrometry-solutions-for-maldi-imaging-metabolomics-proteoform-profiling-and-toxicology-at-asms-2017-300468319.html
SOURCE Bruker Corporation